Blockchain Registration Transaction Record

VolitionRx's Nu.Q Vet Assay Achieves 97% Specificity in Feline Lymphoma Detection

VolitionRx submits clinical manuscript for Nu.Q Vet Feline assay, achieving 97% specificity in detecting lymphoma in cats. A $5 million milestone awaits publication. Learn more about this liquid biopsy test for feline cancer.

This news matters because it brings us closer to a non-invasive, blood-based test for detecting cancer in cats, a common and often fatal disease in companion animals. Early detection can significantly improve treatment outcomes and quality of life for pets, while also reducing veterinary costs for owners. For VolitionRx, successful commercialization could open a new revenue stream and strengthen its position in the veterinary diagnostics market, potentially leading to similar breakthroughs in human cancer detection.